NEURO-COMPASS.EDUCATION IS A FREE, COMPREHENSIVE, PRACTICAL MEDICAL EDUCATION RESOURCE DEVELOPED BY HEALTHCARE PROFESSIONALS FOR HEALTHCARE PROFESSIONALS

DO YOU AGREE WITH THEIR DEFINITION OF AGGRESSIVE MS?

WHEN DO I NEED TO REQUEST AN MRI FOR THIS PATIENT?

PERMANENT OR REVERSIBLE?

Join Neuro-Compass

Neuro-Compass.education will only use your personal details for the purposes of the administration of the site in accordance with our Privacy Policy




Where experts are talking MS

• Hot topics • Practice points • Diagnosis • Immunopathology
• MS imaging • Measuring disease activity • Treatment safety monitoring

  • Professor David Bates (Chair)
    Neuro-Compass will provide an up to date summary of all aspects of the science behind MS and reasoned advice on Diagnosis, Therapy, Monitoring and Support to assist medical staff treating people with MS in their day to day activities and learning Professor David Bates (Chair) (Emeritus Professor of Clinical Neurology), University of Newcastle-upon-Tyne, UK
  • Professor Paul Matthews
    Neuro-Compass promises just the kind of authoritative, brief and practical summaries for MS clinicians that I need to keep fully up-to-date with a rapidly changing management area Professor Paul Matthews (Edmond and Lily Safra Chair and Head of the new Division of Brain Sciences), Department of Medicine of Imperial College, London, UK.
  • Dr James Overell
    Neuro-compass provides easy to access information, and honest and practical guidance from experts in the field, to enable clinicians to excel in the day-to-day care that they provide. Dr James Overell (Consultant Neurologist ), Institute of Neurological Sciences (INS), Glasgow, UK

Topics covered on
Neuro-Compass.education include:

  • Risk Factors for MS Environmental and genetic risk factors for multiple sclerosis.
  • Pathophysiology of MS Pathology, pathogenesis and immunopathology of multiple sclerosis.
  • Diagnosis of MS Multiple sclerosis subtypes and their prognosis (relapsing-remitting, secondary progressive, primary progressive and clinically isolated syndrome, as well as paediatric multiple sclerosis and radiologically isolated syndrome); the Lublin classification scheme; McDonald diagnostic criteria; and differential diagnosis.
  • Measures of Disease Activity Evaluating relapses, disability progression, cognition, physical function, fatigue and other symptoms of multiple sclerosis; expert commentaries on patient assessment tools for measuring disease activity and other symptoms, such as the Expanded Disability Status Scale (EDSS), Brief International Cognitive Assessment for MS (BICAMS), and MS Quality of Life Index (MSQoLI).

TREATMENT OPTIONS

Important considerations before treatment initiation and switching between disease-modifying therapies: summaries of the efficacy (annualised relapse rates; disability progression; magnetic resonance imaging) and safety profiles from key trials; pre-treatment monitoring requirements, symptomatic treatments for other multiple sclerosis symptoms such as cognition, and treatment recommendations based on published treatment algorithms.

During treatment

How to monitor the efficacy of disease-modifying therapy; safety monitoring requirements, and how to manage
side effects.

Stopping treatment

Safety monitoring requirements after stopping a disease-modifying therapy.